Author Interviews, Cost of Health Care / 23.07.2018
Defensive Medicine is Real and Raises Health Care Costs
MedicalResearch.com Interview with:
Jonathan Gruber PhD
Department of Economics, E52-434
MIT
Cambridge, MA 02139
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: There is a large literature trying to estimate the extent of 'defensive medicine' by looking at what happens when it gets harder to sue and/or you can win less money. But there have been no studies of what happens if you just get rid of the right to sue. That's what we have with active duty patients treated on a military base.
The main finding is that when patients can't sue they are treated about 5% less intensively. Much of the effect appears to arise from fewer diagnostic tests.
Jonathan Gruber PhD
Department of Economics, E52-434
MIT
Cambridge, MA 02139
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: There is a large literature trying to estimate the extent of 'defensive medicine' by looking at what happens when it gets harder to sue and/or you can win less money. But there have been no studies of what happens if you just get rid of the right to sue. That's what we have with active duty patients treated on a military base.
The main finding is that when patients can't sue they are treated about 5% less intensively. Much of the effect appears to arise from fewer diagnostic tests.


















Dr. Hernandez[/caption]
Inmaculada Hernandez, PharmD, PhD
Assistant Professor of Pharmacy and Therapeutics
University of Pittsburgh School of Pharmacy
Pittsburgh, PA 1526
MedicalResearch.com: What is the background for this study?
Response: A few months ago, the results of the FOURIER trial were published. This trial was the first one to evaluate the efficacy of PCSK9 inhibitors in the prevention of cardiovascular events, since the approval of these agents was based on trials that evaluated their efficacy in reducing levels of LDL-C. The results of the FOURIER trial did not meet the expectations generated by prior studies that had simulated how much the risk of cardiovascular events should decrease based on the observed reduction in LDL-C levels. A few hours after the publication of the results of the FOURIER trial, Amgen (evolocumab´s manufacturer) announced that it would be willing to engage in contracts where the cost of evolocumab would be refunded for those patients who suffer a heart attack or a stroke while using the drug.



